Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy

NCT04378075 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT04378075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04378075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Lead sponsor
PTC Therapeutics
Phase
Phase 2/3
Overall status
Terminated
Start date
September 28, 2020
Completion date
December 27, 2023
Enrollment
68 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

alpers disease, alpers syndrome, drug resistant epilepsy, leigh disease, leigh syndrome, mitochondrial diseases, mitochondrial encephalopathy (melas), pontocerebellar hypoplasia type 6 (pch6)